LAUSR

Lymphoma refers to a specialized category of blood cancers which is characterized by lymph node enlargement, reduced body weight, prolonged tiredness and fever associated with sweats. Traditional treatment strategies involve chemotherapy, radiation therapy, targeted therapy, and surgery. Copanlisib has emerged as a very potent drug which acts through inhibiting PI3K enzyme. FDA has approved it for specific treatment of follicular Lymphoma in September 2017. Copanlisib induces tumor cell death along with prevention of proliferation of dominant malignant β-cells. Copanlisib has a large volume of distribution i.e. 871L (%CV 47.4), plasma protein binding upto 15.8%, plasma half-life(t1/2) of 39.1h and mean systemic plasma clearance 18.9 L/h (%CV 51.2). In the present review various aspects related to Copanlisib have been summarized which include pathophysiology, synthetic strategy, pharmacokinetics, pharmacodynamics and clinical studies. A special emphasis is given on various reported adverse effect and in silico/ in vivo studies conducted on Copanlisib.